Tissue Repair: Receives second US patent for Glucoprime

Must read

Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

Tissue Repair Receives second US patent for Glucoprime

  • Tissue Repair (TRP) receives a second US patent for its topical skin treatment active ingredient, Glucoprime
  • Glucoprime is an active pharmaceutical ingredient (API) used to treat skin conditions like burns, pressure ulcers and post-procedure wounds whether it be surgical or cosmetic
  • This latest patent grants TissueRepair with exclusive rights to use Glucoprime as a topical application to treat a large number of skin conditions
  • It follows TRP’s first patent approval in April 2022 which granted the company exclusive rights to the method of manufacturing
  • TRP shares are up 6.45 per cent to close at 33 cents
- Advertisement -
Exit mobile version